source
- With $97M, Latus pursues a different kind of Huntington’s gene therapyThe therapy is part of a plan to develop gene therapies that can be efficiently delivered at lower doses, enabling them to be used against more than just “ultra-rare” conditions.BioPharma Dive · 2mo ago↗ source
- Biotech has a new startup model: Small team, big check and Chinese assetsA new flavor of company is shaking up how biotechs are built. Instead of launching with eye-popping early-stage science or a new platform, there's a surge of startups with small teams, large checks…Endpoints · 2mo ago↗ source
- Windward Bio gets $165M to take China-derived drug into Phase 3 asthma trialA Swiss biotech with two experimental medicines from China, plus an in-house discovery team, has brought in $165 million to advance into late-stage testing. The startup, Windward Bio, has raised a ...